Descriptive statistics of the three subcohorts (all patients, tumor tissue, and plasma levels).
| Characteristic . | Missing . | N = 1,701 . | N = 998 . | N = 275 . |
|---|---|---|---|---|
| n . | n (%); Median (IQR) . | n (%); Median (IQR) . | n (%); Median (IQR) . | |
| rs6852762 | 1 | |||
| GG | 1,134 (67) | 663 (66) | 174 (63) | |
| GA | 508 (30) | 298 (30) | 90 (33) | |
| AA | 58 (3.4) | 37 (3.7) | 11 (4.0) | |
| rs1714014 | 4 | |||
| TT | 1,018 (60) | 604 (61) | 169 (62) | |
| TC | 580 (34) | 346 (35) | 96 (35) | |
| CC | 99 (5.8) | 46 (4.6) | 9 (3.3) | |
| rs4865180 | 22 | |||
| TT | 950 (57) | 571 (58) | 164 (61) | |
| TG | 604 (36) | 356 (36) | 91 (34) | |
| GG | 125 (7.4) | 64 (6.5) | 16 (5.9) | |
| rs9992658 | 0 | |||
| AA | 1,539 (90) | 901 (90) | 255 (93) | |
| AC | 157 (9.2) | 94 (9.4) | 19 (6.9) | |
| CC | 5 (0.3) | 3 (0.3) | 1 (0.4) | |
| rs10004910 | 21 | |||
| AA | 569 (34) | 317 (32) | 89 (33) | |
| AG | 791 (47) | 482 (49) | 138 (51) | |
| GG | 320 (19) | 183 (19) | 45 (17) | |
| Age at inclusion | 62 (52, 69) | 61 (52, 68) | 58 (48, 64) | |
| BMI ≥ 25 kg/m2 | 101 | 836 (52) | 480 (49) | 141 (51) |
| Screening detected (ages 45–74) | 303 | 968 (69) | 554 (66) | 125 (58) |
| Tumor size: pT2/3/4 | 0 | 441 (26) | 267 (27) | 106 (39) |
| Nodal status: pN1/2/3 | 2 | 579 (34) | 379 (38) | 134 (49) |
| Grade III | 6 | 470 (28) | 253 (25) | 73 (27) |
| ER positive | 2 | 1,504 (89) | 875 (88) | 225 (82) |
| PR positive | 2 | 1,214 (71) | 707 (71) | 170 (62) |
| HER2 positive | 66 | 175 (11) | 107 (11) | 41 (17) |
| TNBC | 8 | 129 (7.6) | 75 (7.6) | 25 (9.2) |
| Main histological type | 0 | |||
| Mainly ductal (NST) | 1,366 (80) | 806 (81) | 215 (78) | |
| Mainly lobular | 194 (11) | 115 (12) | 30 (11) | |
| Other or mixed | 141 (8.3) | 77 (7.7) | 30 (11) | |
| Chemotherapy | 0 | 488 (29) | 253 (25) | 79 (29) |
| Radiotherapy | 0 | 1,129 (66) | 636 (64) | 178 (65) |
| Trastuzumab | 0 | 124 (7.3) | 69 (6.9) | 21 (7.6) |
| Tamoxifen | 0 | 897 (53) | 563 (56) | 150 (55) |
| Aromatase inhibitors | 0 | 691 (41) | 363 (36) | 107 (39) |
| Characteristic . | Missing . | N = 1,701 . | N = 998 . | N = 275 . |
|---|---|---|---|---|
| n . | n (%); Median (IQR) . | n (%); Median (IQR) . | n (%); Median (IQR) . | |
| rs6852762 | 1 | |||
| GG | 1,134 (67) | 663 (66) | 174 (63) | |
| GA | 508 (30) | 298 (30) | 90 (33) | |
| AA | 58 (3.4) | 37 (3.7) | 11 (4.0) | |
| rs1714014 | 4 | |||
| TT | 1,018 (60) | 604 (61) | 169 (62) | |
| TC | 580 (34) | 346 (35) | 96 (35) | |
| CC | 99 (5.8) | 46 (4.6) | 9 (3.3) | |
| rs4865180 | 22 | |||
| TT | 950 (57) | 571 (58) | 164 (61) | |
| TG | 604 (36) | 356 (36) | 91 (34) | |
| GG | 125 (7.4) | 64 (6.5) | 16 (5.9) | |
| rs9992658 | 0 | |||
| AA | 1,539 (90) | 901 (90) | 255 (93) | |
| AC | 157 (9.2) | 94 (9.4) | 19 (6.9) | |
| CC | 5 (0.3) | 3 (0.3) | 1 (0.4) | |
| rs10004910 | 21 | |||
| AA | 569 (34) | 317 (32) | 89 (33) | |
| AG | 791 (47) | 482 (49) | 138 (51) | |
| GG | 320 (19) | 183 (19) | 45 (17) | |
| Age at inclusion | 62 (52, 69) | 61 (52, 68) | 58 (48, 64) | |
| BMI ≥ 25 kg/m2 | 101 | 836 (52) | 480 (49) | 141 (51) |
| Screening detected (ages 45–74) | 303 | 968 (69) | 554 (66) | 125 (58) |
| Tumor size: pT2/3/4 | 0 | 441 (26) | 267 (27) | 106 (39) |
| Nodal status: pN1/2/3 | 2 | 579 (34) | 379 (38) | 134 (49) |
| Grade III | 6 | 470 (28) | 253 (25) | 73 (27) |
| ER positive | 2 | 1,504 (89) | 875 (88) | 225 (82) |
| PR positive | 2 | 1,214 (71) | 707 (71) | 170 (62) |
| HER2 positive | 66 | 175 (11) | 107 (11) | 41 (17) |
| TNBC | 8 | 129 (7.6) | 75 (7.6) | 25 (9.2) |
| Main histological type | 0 | |||
| Mainly ductal (NST) | 1,366 (80) | 806 (81) | 215 (78) | |
| Mainly lobular | 194 (11) | 115 (12) | 30 (11) | |
| Other or mixed | 141 (8.3) | 77 (7.7) | 30 (11) | |
| Chemotherapy | 0 | 488 (29) | 253 (25) | 79 (29) |
| Radiotherapy | 0 | 1,129 (66) | 636 (64) | 178 (65) |
| Trastuzumab | 0 | 124 (7.3) | 69 (6.9) | 21 (7.6) |
| Tamoxifen | 0 | 897 (53) | 563 (56) | 150 (55) |
| Aromatase inhibitors | 0 | 691 (41) | 363 (36) | 107 (39) |
Descriptive statistics of the three subcohorts (all patients, tumor tissue, and plasma levels).
| Characteristic . | Missing . | N = 1,701 . | N = 998 . | N = 275 . |
|---|---|---|---|---|
| n . | n (%); Median (IQR) . | n (%); Median (IQR) . | n (%); Median (IQR) . | |
| rs6852762 | 1 | |||
| GG | 1,134 (67) | 663 (66) | 174 (63) | |
| GA | 508 (30) | 298 (30) | 90 (33) | |
| AA | 58 (3.4) | 37 (3.7) | 11 (4.0) | |
| rs1714014 | 4 | |||
| TT | 1,018 (60) | 604 (61) | 169 (62) | |
| TC | 580 (34) | 346 (35) | 96 (35) | |
| CC | 99 (5.8) | 46 (4.6) | 9 (3.3) | |
| rs4865180 | 22 | |||
| TT | 950 (57) | 571 (58) | 164 (61) | |
| TG | 604 (36) | 356 (36) | 91 (34) | |
| GG | 125 (7.4) | 64 (6.5) | 16 (5.9) | |
| rs9992658 | 0 | |||
| AA | 1,539 (90) | 901 (90) | 255 (93) | |
| AC | 157 (9.2) | 94 (9.4) | 19 (6.9) | |
| CC | 5 (0.3) | 3 (0.3) | 1 (0.4) | |
| rs10004910 | 21 | |||
| AA | 569 (34) | 317 (32) | 89 (33) | |
| AG | 791 (47) | 482 (49) | 138 (51) | |
| GG | 320 (19) | 183 (19) | 45 (17) | |
| Age at inclusion | 62 (52, 69) | 61 (52, 68) | 58 (48, 64) | |
| BMI ≥ 25 kg/m2 | 101 | 836 (52) | 480 (49) | 141 (51) |
| Screening detected (ages 45–74) | 303 | 968 (69) | 554 (66) | 125 (58) |
| Tumor size: pT2/3/4 | 0 | 441 (26) | 267 (27) | 106 (39) |
| Nodal status: pN1/2/3 | 2 | 579 (34) | 379 (38) | 134 (49) |
| Grade III | 6 | 470 (28) | 253 (25) | 73 (27) |
| ER positive | 2 | 1,504 (89) | 875 (88) | 225 (82) |
| PR positive | 2 | 1,214 (71) | 707 (71) | 170 (62) |
| HER2 positive | 66 | 175 (11) | 107 (11) | 41 (17) |
| TNBC | 8 | 129 (7.6) | 75 (7.6) | 25 (9.2) |
| Main histological type | 0 | |||
| Mainly ductal (NST) | 1,366 (80) | 806 (81) | 215 (78) | |
| Mainly lobular | 194 (11) | 115 (12) | 30 (11) | |
| Other or mixed | 141 (8.3) | 77 (7.7) | 30 (11) | |
| Chemotherapy | 0 | 488 (29) | 253 (25) | 79 (29) |
| Radiotherapy | 0 | 1,129 (66) | 636 (64) | 178 (65) |
| Trastuzumab | 0 | 124 (7.3) | 69 (6.9) | 21 (7.6) |
| Tamoxifen | 0 | 897 (53) | 563 (56) | 150 (55) |
| Aromatase inhibitors | 0 | 691 (41) | 363 (36) | 107 (39) |
| Characteristic . | Missing . | N = 1,701 . | N = 998 . | N = 275 . |
|---|---|---|---|---|
| n . | n (%); Median (IQR) . | n (%); Median (IQR) . | n (%); Median (IQR) . | |
| rs6852762 | 1 | |||
| GG | 1,134 (67) | 663 (66) | 174 (63) | |
| GA | 508 (30) | 298 (30) | 90 (33) | |
| AA | 58 (3.4) | 37 (3.7) | 11 (4.0) | |
| rs1714014 | 4 | |||
| TT | 1,018 (60) | 604 (61) | 169 (62) | |
| TC | 580 (34) | 346 (35) | 96 (35) | |
| CC | 99 (5.8) | 46 (4.6) | 9 (3.3) | |
| rs4865180 | 22 | |||
| TT | 950 (57) | 571 (58) | 164 (61) | |
| TG | 604 (36) | 356 (36) | 91 (34) | |
| GG | 125 (7.4) | 64 (6.5) | 16 (5.9) | |
| rs9992658 | 0 | |||
| AA | 1,539 (90) | 901 (90) | 255 (93) | |
| AC | 157 (9.2) | 94 (9.4) | 19 (6.9) | |
| CC | 5 (0.3) | 3 (0.3) | 1 (0.4) | |
| rs10004910 | 21 | |||
| AA | 569 (34) | 317 (32) | 89 (33) | |
| AG | 791 (47) | 482 (49) | 138 (51) | |
| GG | 320 (19) | 183 (19) | 45 (17) | |
| Age at inclusion | 62 (52, 69) | 61 (52, 68) | 58 (48, 64) | |
| BMI ≥ 25 kg/m2 | 101 | 836 (52) | 480 (49) | 141 (51) |
| Screening detected (ages 45–74) | 303 | 968 (69) | 554 (66) | 125 (58) |
| Tumor size: pT2/3/4 | 0 | 441 (26) | 267 (27) | 106 (39) |
| Nodal status: pN1/2/3 | 2 | 579 (34) | 379 (38) | 134 (49) |
| Grade III | 6 | 470 (28) | 253 (25) | 73 (27) |
| ER positive | 2 | 1,504 (89) | 875 (88) | 225 (82) |
| PR positive | 2 | 1,214 (71) | 707 (71) | 170 (62) |
| HER2 positive | 66 | 175 (11) | 107 (11) | 41 (17) |
| TNBC | 8 | 129 (7.6) | 75 (7.6) | 25 (9.2) |
| Main histological type | 0 | |||
| Mainly ductal (NST) | 1,366 (80) | 806 (81) | 215 (78) | |
| Mainly lobular | 194 (11) | 115 (12) | 30 (11) | |
| Other or mixed | 141 (8.3) | 77 (7.7) | 30 (11) | |
| Chemotherapy | 0 | 488 (29) | 253 (25) | 79 (29) |
| Radiotherapy | 0 | 1,129 (66) | 636 (64) | 178 (65) |
| Trastuzumab | 0 | 124 (7.3) | 69 (6.9) | 21 (7.6) |
| Tamoxifen | 0 | 897 (53) | 563 (56) | 150 (55) |
| Aromatase inhibitors | 0 | 691 (41) | 363 (36) | 107 (39) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
